Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Meister

Showing results (31-40 of 117) with videos related to

Pageof 12
Sort By:
Scientific Reports|September 20, 2016
Mutation analysis of circulating plasma DNA to determine response to EGFR tyrosine kinase inhibitor therapy of lung adenocarcinoma patientsAnja Lisa Riediger, Steffen Dietz, Uwe Schirmer, et al.
Oncotarget|October 8, 2016
Glycodelin is a potential novel follow-up biomarker for malignant pleural mesotheliomaMarc A Schneider, Thomas Muley, Nicolas C Kahn, et al.
American Journal of Physiology. Heart and Circulatory Physiology|January 15, 2002
Impaired parasympathetic heart rate control in mice with a reduction of functional G protein betagamma-subunitsJosef Gehrmann, Michael Meister, Colin T Maguire, et al.
Molecular Imaging and Biology|January 24, 2019
PET/CT Imaging of NSCLC with a α<sub>v</sub>β<sub>6</sub> Integrin-Targeting PeptidePaul Flechsig, Thomas Lindner, Anastasia Loktev, et al.
International Journal of Oncology|December 12, 2018
Pathways regulating the expression of the immunomodulatory protein glycodelin in non‑small cell lung cancerRebecca Weber, Michael Meister, Thomas Muley, et al.
Anticancer Research|July 2, 2014
Comparison of two ERCC1 antibodies as prognostic and predictive biomarkers for early non-small cell lung cancerThomas R Muley, Maria Sianidou, Michael Thomas, et al.
Histopathology|August 14, 2012
Large-scale comparative analyses of immunomarkers for diagnostic subtyping of non-small-cell lung cancer biopsiesArne Warth, Thomas Muley, Esther Herpel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 7, 2012
The novel histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification system of lung adenocarcinoma is a stage-independent predictor of survivalArne Warth, Thomas Muley, Michael Meister, et al.
Biological Chemistry|August 1, 2009
Specific induction of migration and invasion of pancreatic carcinoma cells by RhoC, which differs from RhoA in its localisation and activityKarin-Almut Dietrich, Rene Schwarz, Martina Liska, et al.
Frontiers in Oncology|February 17, 2022
Acute Phase Proteins as Early Predictors for Immunotherapy Response in Advanced NSCLC: An Explorative StudyMarc A Schneider, Adriana Rozy, Sabine Wrenger, et al.
Pageof 12

Showing results (31-40 of 117) with videos related to

Sort By:
Pageof 12
Scientific Reports|September 20, 2016
Mutation analysis of circulating plasma DNA to determine response to EGFR tyrosine kinase inhibitor therapy of lung adenocarcinoma patientsAnja Lisa Riediger, Steffen Dietz, Uwe Schirmer, et al.
Oncotarget|October 8, 2016
Glycodelin is a potential novel follow-up biomarker for malignant pleural mesotheliomaMarc A Schneider, Thomas Muley, Nicolas C Kahn, et al.
American Journal of Physiology. Heart and Circulatory Physiology|January 15, 2002
Impaired parasympathetic heart rate control in mice with a reduction of functional G protein betagamma-subunitsJosef Gehrmann, Michael Meister, Colin T Maguire, et al.
Molecular Imaging and Biology|January 24, 2019
PET/CT Imaging of NSCLC with a α<sub>v</sub>β<sub>6</sub> Integrin-Targeting PeptidePaul Flechsig, Thomas Lindner, Anastasia Loktev, et al.
International Journal of Oncology|December 12, 2018
Pathways regulating the expression of the immunomodulatory protein glycodelin in non‑small cell lung cancerRebecca Weber, Michael Meister, Thomas Muley, et al.
Anticancer Research|July 2, 2014
Comparison of two ERCC1 antibodies as prognostic and predictive biomarkers for early non-small cell lung cancerThomas R Muley, Maria Sianidou, Michael Thomas, et al.
Histopathology|August 14, 2012
Large-scale comparative analyses of immunomarkers for diagnostic subtyping of non-small-cell lung cancer biopsiesArne Warth, Thomas Muley, Esther Herpel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 7, 2012
The novel histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification system of lung adenocarcinoma is a stage-independent predictor of survivalArne Warth, Thomas Muley, Michael Meister, et al.
Biological Chemistry|August 1, 2009
Specific induction of migration and invasion of pancreatic carcinoma cells by RhoC, which differs from RhoA in its localisation and activityKarin-Almut Dietrich, Rene Schwarz, Martina Liska, et al.
Frontiers in Oncology|February 17, 2022
Acute Phase Proteins as Early Predictors for Immunotherapy Response in Advanced NSCLC: An Explorative StudyMarc A Schneider, Adriana Rozy, Sabine Wrenger, et al.
Pageof 12